8 results
to offer continuation of BIBF 1020 treatment for patients with IPF who have completed a prior clinical trial with that drug.establish the long term tolerability and safety profile of BIBF 1120 in IPF.
The objective of the trial is to confirm efficacy and a favorable benefit-risk ratio for BIBF 1120 in the treatment of IPF at the dose of 150 mg bid compared to placebo.
The aim of this extension trial is to provide BIBF 1120 treatment for all patients who have completed the 52 weeks treatment period and the follow up period in the phase III placebo controlled parent trial 1199.34, who may have experienced benefit…
This study consists of two research questions: 1. Which treatment (INCS on daily bases versus INCS on demand or versus oral antihistamines on demand) is most effective in reducing nasal symptoms and ocular symptoms in children with mild to moderate…
Objective: Evaluate the safety and effectiveness of two cementless Taperloc versions (Taperloc complete versus Taperloc complete Microplasty)
Establish the non-inferiority of the R3 acetabular system with a high survival rate at 10 years fu (at least 90%). Second objective is to establish good clinical results by means of (Harris Hip Score, Hoos, UCLA and radiologic failures (like…
BoneMaster ITo perform a comparative assessment between the clinical, bone remodelling, and radiographic outcomes (as measured with RSA) of the conventional Hydroxyl-Apetite (HA) Taperloc stem compared with Taperloc stem with additional BoneMaster®…
The goal of this clinical investigation is to assess the early migration and bone remodeling of the Symax hip stem and the Trident HA coated or Trident Tritanium acetabulum component with RSA and 18-F PET CT Also the sensitivity of the RSA…